CONFLICT OF INTEREST All authors are employees and stockholders of Catalent Pharma Solutions. REFERENCES , , , , , , & (2022). Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools. Biotechnology and Bioengineering, 199(2), 663–666. https://doi.org/10.1002/bit.27995 (2006). An alternative method for the rapid generation of stable, high-expressing mammalian cell lines. BioProcessing Journal, 5(4), 36–42. https://doi.org/10.12665/j54.bleck (2012).